Trimeric gp120-specific bovine monoclonal antibodies require cysteine and aromatic residues in CDRH3 for high affinity binding to HIV Env

mAbs

Volumn 9, Issue 3, 2017, Pages 550-566

  Heydarchi, Behnaz ^a   Center, Rob J ^a,b   Bebbington, Jonathan ^a   Cuthbertson, Jack ^a   Gonelli, Christopher ^a   Khoury, Georges ^a   Mackenzie, Charlene ^a   Lichtfuss, Marit ^a   Rawlin, Grant ^a   Muller, Brian ^a   Purcell, Damian ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b BURNET INSTITUTE   (Australia)

Author keywords

Aromatic residues; bovine; CDRH3; Cysteine; HIV; monoclonal antibodies; variable region

Indexed keywords

CD4 ANTIGEN; COMPLEMENTARITY DETERMINING REGION 1; COMPLEMENTARITY DETERMINING REGION 2; COMPLEMENTARITY DETERMINING REGION 3; GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 140; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2; IMMUNOGLOBULIN G3; IMMUNOGLOBULIN HEAVY CONSTANT DELTA; IMMUNOGLOBULIN HEAVY CONSTANT DELTA 2; IMMUNOGLOBULIN HEAVY CONSTANT DELTA 3; IMMUNOGLOBULIN HEAVY CONSTANT DELTA 4; IMMUNOGLOBULIN HEAVY CONSTANT DELTA 5; IMMUNOGLOBULIN HEAVY CONSTANT DELTA 7; IMMUNOGLOBULIN HEAVY CONSTANT DELTA 8; MONOCLONAL ANTIBODY; PEPTIDES AND PROTEINS; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN; CYSTEINE; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY;

ANIMAL CELL; CONTROLLED STUDY; ENZYME LINKED IMMUNOSPOT ASSAY; FLOW CYTOMETRY; GENE MUTATION; IMMUNIZATION; MUTAGENESIS; NONHUMAN; POLYMERASE CHAIN REACTION; PROTEIN BINDING; PROTEIN EXPRESSION; SEQUENCE ANALYSIS; SERODIAGNOSIS; AMINO ACID SEQUENCE; ANIMAL; BOVINE; CHEMISTRY; COMPLEMENTARITY DETERMINING REGION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOGLOBULIN VARIABLE REGION; IMMUNOLOGY; PROCEDURES; PROTEIN ENGINEERING; VETERINARY;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, MONOCLONAL; CATTLE; COMPLEMENTARITY DETERMINING REGIONS; CYSTEINE; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP120; HIV INFECTIONS; HUMANS; IMMUNOGLOBULIN VARIABLE REGION; PROTEIN ENGINEERING;

EID: 85013391659     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.1080/19420862.2016.1270491     Document Type: Article

References (88)

1. Gunthard HF, Saag MS, Benson CA, del Rio C, Eron JJ, Gallant JE, Hoy JF, Mugavero MJ, Sax PE, Thompson MA, et al. Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults 2016 Recommendations of the International Antiviral Society-USA Panel. JAMA 2016; 316(2):191-210; PMID:27404187; http://dx.doi.org/10.1001/jama.2016.8900
2. Klein F, Mouquet H, Dosenovic P, Scheid JF, Scharf L, Nussenzweig MC. Antibodies in HIV-1 vaccine development and therapy. Science 2013; 341(6151):1199-204; PMID:24031012; http://dx.doi.org/10.1126/science.1241144
3. Watkins JD, Siddappa NB, Lakhashe SK, Humbert M, Sholukh A, Hemashettar G, Wong YL, Yoon JK, Wang W, Novembre FJ, et al. An anti-HIV-1 V3 loop antibody fully protects cross-clade and elicits T-cell immunity in macaques mucosally challenged with an R5 clade C SHIV. PLoS One 2011; 6(3):e18207; PMID:21483815; http://dx.doi.org/10.1371/journal.pone.0018207
4. Mascola JR, Montefiori DC. The role of antibodies in HIV vaccines. Annu Rev Immunol 2010; 28:413-44; PMID:20192810; http://dx.doi.org/10.1146/annurev-immunol-030409-101256
5. Kramer VG, Siddappa NB, Ruprecht RM. Passive immunization as tool to identify protective HIV-1 Env epitopes. Curr HIV Res 2007; 5(6):642-55; PMID:18045119; http://dx.doi.org/10.2174/157016207782418506
6. Casadevall A, Dadachova E, Pirofski LA. Passive antibody therapy for infectious diseases. Nat Rev Microbiol 2004; 2(9):695-703; PMID:15372080; http://dx.doi.org/10.1038/nrmicro974
7. Melchers M, Bontjer I, Tong T, Chung NP, Klasse PJ, Eggink D, Montefiori DC, Gentile M, Cerutti A, Olson WC, et al. Targeting HIV-1 envelope glycoprotein trimers to B cells by using APRIL improves antibody responses. J Virol 2012; 86(5):2488-500; PMID:22205734; http://dx.doi.org/10.1128/JVI.06259-11
8. Beddows S, Franti M, Dey AK, Kirschner M, Iyer SP, Fisch DC, Ketas T, Yuste E, Desrosiers RC, Klasse PJ, et al. A comparative immunogenicity study in rabbits of disulfide-stabilized, proteolytically cleaved, soluble trimeric human immunodeficiency virus type 1 gp140, trimeric cleavage-defective gp140 and monomeric gp120. Virology 2007; 360(2):329-40; PMID:17126869; http://dx.doi.org/10.1016/j.virol.2006.10.032
9. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, Premsri N, Namwat C, de Souza M, Adams E, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009; 361(23):2209-20; PMID:19843557; http://dx.doi.org/10.1056/NEJMoa0908492
10. Burton DR, Desrosiers RC, Doms RW, Koff WC, Kwong PD, Moore JP, Nabel GJ, Sodroski J, Wilson IA, Wyatt RT. HIV vaccine design and the neutralizing antibody problem. Nat Immunol 2004; 5(3):233-6; PMID:14985706; http://dx.doi.org/10.1038/ni0304-233
11. Kovacs JM, Nkolola JP, Peng H, Cheung A, Perry J, Miller CA, Seaman MS, Barouch DH, Chen B. HIV-1 envelope trimer elicits more potent neutralizing antibody responses than monomeric gp120. Proc Natl Acad Sci U S A 2012; 109(30):12111-6; PMID:22773820; http://dx.doi.org/10.1073/pnas.1204533109
12. Kang YK, Andjelic S, Binley JM, Crooks ET, Franti M, Iyer SP, Donovan GP, Dey AK, Zhu P, Roux KH, et al. Structural and immunogenicity studies of a cleaved, stabilized envelope trimer derived from subtype A HIV-1. Vaccine 2009; 27(37):5120-32; PMID:19567243; http://dx.doi.org/10.1016/j.vaccine.2009.06.037
13. McCoy LE, Quigley AF, Strokappe NM, Bulmer-Thomas B, Seaman MS, Mortier D, Rutten L, Chander N, Edwards CJ, Ketteler R, et al. Potent and broad neutralization of HIV-1 by a llama antibody elicited by immunization. J Exp Med 2012; 209(6):1091-103; PMID:22641382; http://dx.doi.org/10.1084/jem.20112655
14. Kramski M, Center RJ, Wheatley AK, Jacobson JC, Alexander MR, Rawlin G, Purcell DF. Hyperimmune bovine colostrum as a low-cost, large-scale source of antibodies with broad neutralizing activity for HIV-1 envelope with potential use in microbicides. Antimicrob Agents Chemother 2012; 56(8):4310-9; PMID:22664963; http://dx.doi.org/10.1128/AAC.00453-12
15. Heydarchi B, Center RJ, Gonelli C, Muller B, Mackenzie C, Khoury G, Lichtfuss M, Rawlin G, Purcell DF. Repeated Vaccination of Cows with HIV Env gp140 during Subsequent Pregnancies Elicits and Sustains an Enduring Strong Env-Binding and Neutralising Antibody Response. PLoS One 2016; 11(6):e0157353; PMID:27300145; http://dx.doi.org/10.1371/journal.pone.0157353
16. Ohno S, Mori N, Matsunaga T. Antigen-binding specificities of antibodies are primarily determined by seven residues of VH. Proc Natl Acad Sci U S A 1985; 82(9):2945-9; PMID:3921967; http://dx.doi.org/10.1073/pnas.82.9.2945
17. Fugmann SD, Lee AI, Shockett PE, Villey IJ, Schatz DG. The RAG proteins and V(D)J recombination:complexes, ends, and transposition. Annu Rev Immunol 2000; 18:495-527; PMID:10837067; http://dx.doi.org/10.1146/annurev.immunol.18.1.495
18. Smider V, Chu G. The end-joining reaction in V(D)J recombination. Semin Immunol 1997; 9(3):189-97; PMID:9200330; http://dx.doi.org/10.1006/smim.1997.0070
19. Tonegawa S. Somatic generation of antibody diversity. Nature 1983; 302(5909):575-81; PMID:6300689; http://dx.doi.org/10.1038/302575a0
20. Lopez O, Perez C, Wylie D. A single VH family and long CDR3s are the targets for hypermutation in bovine immunoglobulin heavy chains. Immunol Rev 1998; 162:55-66; PMID:9602352; http://dx.doi.org/10.1111/j.1600-065X.1998.tb01429.x
21. Di Noia JM, Neuberger MS. Molecular mechanisms of antibody somatic hypermutation. Annu Rev Biochem 2007; 76:1-22; PMID:17328676; http://dx.doi.org/10.1146/annurev.biochem.76.061705.090740
22. Wrammert J, Koutsonanos D, Li GM, Edupuganti S, Sui J, Morrissey M, McCausland M, Skountzou I, Hornig M, Lipkin WI, et al. Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection. J Exp Med 2011; 208(1):181-93; PMID:21220454; http://dx.doi.org/10.1084/jem.20101352
23. Scheid JF, Mouquet H, Feldhahn N, Seaman MS, Velinzon K, Pietzsch J, Ott RG, Anthony RM, Zebroski H, Hurley A, et al. Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals. Nature 2009; 458(7238):636-40; PMID:19287373; http://dx.doi.org/10.1038/nature07930
24. Tiller T, Tsuiji M, Yurasov S, Velinzon K, Nussenzweig MC, Wardemann H. Autoreactivity in human IgG+ memory B cells. Immunity 2007;26(2):205-13; PMID:17306569; http://dx.doi.org/10.1016/j.immuni.2007.01.009
25. Prabakaran P, Zhu Z, Chen W, Gong R, Feng Y, Streaker E, Dimitrov DS. Origin, diversity, and maturation of human antiviral antibodies analyzed by high-throughput sequencing. Front Microbiol 2012; 3:277; PMID:22876240; http://dx.doi.org/10.3389/fmicb.2012.00277
26. Mouquet H, Scheid JF, Zoller MJ, Krogsgaard M, Ott RG, Shukair S, Artyomov MN, Pietzsch J, Connors M, Pereyra F, et al. Polyreactivity increases the apparent affinity of anti-HIV antibodies by heteroligation. Nature 2010; 467(7315):591-5; PMID:20882016; http://dx.doi.org/10.1038/nature09385
27. Zhou T, Xu L, Dey B, Hessell AJ, Van Ryk D, Xiang SH, Yang X, Zhang MY, Zwick MB, Arthos J, et al. Structural definition of a conserved neutralization epitope on HIV-1 gp120. Nature 2007; 445(7129):732-7; PMID:17301785; http://dx.doi.org/10.1038/nature05580
28. Burton DR, Pyati J, Koduri R, Sharp SJ, Thornton GB, Parren PW, Sawyer LS, Hendry RM, Dunlop N, Nara PL, et al. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science 1994; 266(5187):1024-7; PMID:7973652; http://dx.doi.org/10.1126/science.7973652
29. Pancera M, McLellan JS, Wu X, Zhu J, Changela A, Schmidt SD, Yang Y, Zhou T, Phogat S, Mascola JR, et al. Crystal structure of PG16 and chimeric dissection with somatically related PG9:structure-function analysis of two quaternary-specific antibodies that effectively neutralize HIV-1. J Virol 2010; 84(16):8098-110; PMID:20538861; http://dx.doi.org/10.1128/JVI.00966-10
30. Collis AV, Brouwer AP, Martin AC. Analysis of the antigen combining site:correlations between length and sequence composition of the hypervariable loops and the nature of the antigen. J Mol Biol 2003; 325(2):337-54; PMID:12488099; http://dx.doi.org/10.1016/S0022-2836(02)01222-6
31. Scherer EM, Leaman DP, Zwick MB, McMichael AJ, Burton DR. Aromatic residues at the edge of the antibody combining site facilitate viral glycoprotein recognition through membrane interactions. Proc Natl Acad Sci U S A 2010; 107(4):1529-34; PMID:20080706; http://dx.doi.org/10.1073/pnas.0909680107
32. Ofek G, McKee K, Yang Y, Yang ZY, Skinner J, Guenaga FJ, Wyatt R, Zwick MB, Nabel GJ, Mascola JR, et al. Relationship between antibody 2F5 neutralization of HIV-1 and hydrophobicity of its heavy chain third complementarity-determining region. J Virol 2010; 84(6):2955-62; PMID:20042512; http://dx.doi.org/10.1128/JVI.02257-09
33. Alam SM, Morelli M, Dennison SM, Liao HX, Zhang R, Xia SM, Rits-Volloch S, Sun L, Harrison SC, Haynes BF, et al. Role of HIV membrane in neutralization by two broadly neutralizing antibodies. Proc Natl Acad Sci U S A 2009; 106(48):20234-9; PMID:19906992; http://dx.doi.org/10.1073/pnas.0908713106
34. Julien JP, Huarte N, Maeso R, Taneva SG, Cunningham A, Nieva JL, Pai EF. Ablation of the complementarity-determining region H3 apex of the anti-HIV-1 broadly neutralizing antibody 2F5 abrogates neutralizing capacity without affecting core epitope binding. J Virol 2010; 84(9):4136-47; PMID:20147404; http://dx.doi.org/10.1128/JVI.02357-09
35. Ofek G, Tang M, Sambor A, Katinger H, Mascola JR, Wyatt R, Kwong PD. Structure and mechanistic analysis of the anti-human immunodeficiency virus type 1 antibody 2F5 in complex with its gp41 epitope. J Virol 2004; 78(19):10724-37; PMID:15367639; http://dx.doi.org/10.1128/JVI.78.19.10724-10737.2004
36. Buchacher A, Predl R, Strutzenberger K, Steinfellner W, Trkola A, Purtscher M, Gruber G, Tauer C, Steindl F, Jungbauer A, et al. Generation of human monoclonal antibodies against HIV-1 proteins; electrofusion and Epstein-Barr virus transformation for peripheral blood lymphocyte immortalization. AIDS Res Hum Retroviruses 1994; 10(4):359-69; PMID:7520721; http://dx.doi.org/10.1089/aid.1994.10.359
37. Purtscher M, Trkola A, Gruber G, Buchacher A, Predl R, Steindl F, Tauer C, Berger R, Barrett N, Jungbauer A, et al. A broadly neutralizing human monoclonal antibody against gp41 of human immunodeficiency virus type 1. AIDS Res Hum Retroviruses 1994; 10(12):1651-8; PMID:7888224; http://dx.doi.org/10.1089/aid.1994.10.1651
38. Kong L, Lee JH, Doores KJ, Murin CD, Julien JP, McBride R, Liu Y, Marozsan A, Cupo A, Klasse PJ, et al. Supersite of immune vulnerability on the glycosylated face of HIV-1 envelope glycoprotein gp120. Nat Struct Mol Biol 2013; 20(7):796-803; PMID:23708606; http://dx.doi.org/10.1038/nsmb.2594
39. Kwong PD, Mascola JR. Human antibodies that neutralize HIV-1:identification, structures, and B cell ontogenies. Immunity 2012; 37(3):412-25; PMID:22999947; http://dx.doi.org/10.1016/j.immuni.2012.08.012
40. Mouquet H, Scharf L, Euler Z, Liu Y, Eden C, Scheid JF, Halper-Stromberg A, Gnanapragasam PN, Spencer DI, Seaman MS, et al. Complex-type N-glycan recognition by potent broadly neutralizing HIV antibodies. Proc Natl Acad Sci U S A 2012; 109(47):E3268-77; PMID:23115339; http://dx.doi.org/10.1073/pnas.1217207109
41. Pejchal R, Walker LM, Stanfield RL, Phogat SK, Koff WC, Poignard P, Burton DR, Wilson IA. Structure and function of broadly reactive antibody PG16 reveal an H3 subdomain that mediates potent neutralization of HIV-1. Proc Natl Acad Sci U S A 2010; 107(25):11483-8; PMID:20534513; http://dx.doi.org/10.1073/pnas.1004600107
42. Zemlin M, Klinger M, Link J, Zemlin C, Bauer K, Engler JA, Schroeder, HW, Jr., Kirkham PM. Expressed murine and human CDR-H3 intervals of equal length exhibit distinct repertoires that differ in their amino acid composition and predicted range of structures. J Mol Biol 2003; 334(4):733-49; PMID:14636599; http://dx.doi.org/10.1016/j.jmb.2003.10.007
43. Wu TT, Johnson G, Kabat EA. Length distribution of CDRH3 in antibodies. Proteins 1993; 16(1):1-7; PMID:8497480; http://dx.doi.org/10.1002/prot.340160102
44. Ivanov II, Schelonka RL, Zhuang Y, Gartland GL, Zemlin M, Schroeder HW, Jr. Development of the expressed Ig CDR-H3 repertoire is marked by focusing of constraints in length, amino acid use, and charge that are first established in early B cell progenitors. J Immunol 2005; 174(12):7773-80; PMID:15944280; http://dx.doi.org/10.4049/jimmunol.174.12.7773
45. Wang F, Ekiert DC, Ahmad I, Yu W, Zhang Y, Bazirgan O, Torkamani A, Raudsepp T, Mwangi W, Criscitiello MF, et al. Reshaping antibody diversity. Cell 2013; 153(6):1379-93; PMID:23746848; http://dx.doi.org/10.1016/j.cell.2013.04.049
46. Zhao Y, Jackson SM, Aitken R. The bovine antibody repertoire. Dev Comp Immunol 2006; 30(1-2):175-86; PMID:16054212; http://dx.doi.org/10.1016/j.dci.2005.06.012
47. Sinclair MC, Gilchrist J, Aitken R. Bovine IgG repertoire is dominated by a single diversified VH gene family. J Immunol 1997; 159(8):3883-9; PMID:9378976
48. Saini SS, Allore B, Jacobs RM, Kaushik A. Exceptionally long CDR3H region with multiple cysteine residues in functional bovine IgM antibodies. Eur J Immunol 1999; 29(8):2420-6; PMID:10458755; http://dx.doi.org/10.1002/(SICI)1521-4141(199908)29:08%3c2420::AID-IMMU2420%3e3.0.CO;2-A
49. Kaushik AK, Kehrli, ME, Jr., Kurtz A, Ng S, Koti M, Shojaei F, Saini SS. Somatic hypermutations and isotype restricted exceptionally long CDR3H contribute to antibody diversification in cattle. Vet Immunol Immunopathol 2009; 127(1-2):106-13; PMID:19012969; http://dx.doi.org/10.1016/j.vetimm.2008.09.024
50. Sather DN, Armann J, Ching LK, Mavrantoni A, Sellhorn G, Caldwell Z, Yu X, Wood B, Self S, Kalams S, et al. Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection. J Virol 2009; 83(2):757-69; PMID:18987148; http://dx.doi.org/10.1128/JVI.02036-08
51. Ofek G, Zirkle B, Yang Y, Zhu Z, McKee K, Zhang B, Chuang GY, Georgiev IS, O'Dell S, Doria-Rose N, et al. Structural basis for HIV-1 neutralization by 2F5-like antibodies m66 and m66.6. J Virol 2014; 88(5):2426-41; PMID:24335316; http://dx.doi.org/10.1128/JVI.02837-13
52. West AP, Jr., Diskin R, Nussenzweig MC, Bjorkman PJ. Structural basis for germ-line gene usage of a potent class of antibodies targeting the CD4-binding site of HIV-1 gp120. Proc Natl Acad Sci U S A 2012; 109(30):E2083-90; PMID:22745174; http://dx.doi.org/10.1073/pnas.1208984109
53. Doria-Rose NA, Schramm CA, Gorman J, Moore PL, Bhiman JN, DeKosky BJ, Ernandes MJ, Georgiev IS, Kim HJ, Pancera M, et al. Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies. Nature 2014; 509(7498):55-62; PMID:24590074; http://dx.doi.org/10.1038/nature13036
54. Kramski M, Lichtfuss GF, Navis M, Isitman G, Wren L, Rawlin G, Center RJ, Jaworowski A, Kent SJ, Purcell DFJ. Anti-HIV-1 antibody-dependent cellular cytotoxicity mediated by hyperimmune bovine colostrum IgG. Euro J Immunol 2012; 42(10):2771-81; PMID:22730083; http://dx.doi.org/10.1002/eji.201242469
55. Zhao Y, Kacskovics I, Rabbani H, Hammarström L. Physical Mapping of the Bovine Immunoglobulin Heavy Chain Constant Region Gene Locus. J Biol Chem 2003; 278:35024-32; PMID:12829708; http://dx.doi.org/10.1074/jbc.M301337200
56. Ekman A, Niku N, Liljavirta J, Iivanainen1 A. Bos taurus genome sequence reveals the assortment of immunoglobulin and surrogate light chain genes in domestic cattle. BMC Immunol 2009; 10(22); PMID:19405939; http://dx.doi.org/10.1186/1471-2172-10-22
57. Queen C, Schneider WP, Selick HE, Payne PW, Landolfi NF, Duncan JF, Avdalovic NM, Levitt M, Junghans RP, Waldmann TA. A Humanized Antibody That Binds to the Interleukin-2 Receptor. Proc Natl Acad Sci U S A 1989; 86(24):10029-10033; PMID:2513570; http://dx.doi.org/10.1073/pnas.86.24.10029
58. KOTI M, Kataevab G, Kaushika A. Novel atypical nucleotide insertions specifically at VH–DH junction generate exceptionally long CDR3H in cattle antibodies. Mol Immunol 2010; 47:2119-28; PMID:20435350; http://dx.doi.org/10.1016/j.molimm.2010.02.014
59. Biasini M, Bienert S, Waterhouse A, Arnold K, Studer G, Schmidt T, Kiefer F, Gallo Cassarino T, Bertoni M, Bordoli L, et al. SWISS-MODEL:modelling protein tertiary and quaternary structure using evolutionary information. Nucleic Acids Res 2014; 42(Web Server issue):W252-8; PMID:24782522; http://dx.doi.org/10.1093/nar/gku340
60. Guex N, Peitsch MC, Schwede T. Automated comparative protein structure modeling with SWISS-MODEL and Swiss-PdbViewer:a historical perspective. Electrophoresis 2009; 30(Suppl 1):S162-73; PMID:19517507; http://dx.doi.org/10.1002/elps.200900140
61. Kiefer F, Arnold K, Kunzli M, Bordoli L, Schwede T. The SWISS-MODEL Repository and associated resources. Nucleic Acids Res 2009; 37(Database issue):D387-92; PMID:18931379; http://dx.doi.org/10.1093/nar/gkn750
62. Arnold K, Bordoli L, Kopp J, Schwede T. The SWISS-MODEL workspace:a web-based environment for protein structure homology modelling. Bioinformatics 2006; 22(2):195-201; PMID:16301204; http://dx.doi.org/10.1093/bioinformatics/bti770
63. Doria-Rose NA, Klein RM, Manion MM, O'Dell S, Phogat A, Chakrabarti B, Hallahan CW, Migueles SA, Wrammert J, Ahmed R, et al. Frequency and phenotype of human immunodeficiency virus envelope-specific B cells from patients with broadly cross-neutralizing antibodies. J Virol 2009; 83(1):188-99; PMID:18922865; http://dx.doi.org/10.1128/JVI.01583-08
64. Fondere JM, Huguet MF, Yssel H, Baillat V, Reynes J, van de Perre P, Vendrell JP. Detection of peripheral HIV-1-specific memory B cells in patients untreated or receiving highly active antiretroviral therapy. AIDS 2003; 17(16):2323-30; PMID:14571183; http://dx.doi.org/10.1097/00002030-200311070-00006
65. Sundling C, Martinez P, Soldemo M, Spangberg M, Bengtsson KL, Stertman L, Forsell MN, Karlsson Hedestam GB. Immunization of macaques with soluble HIV type 1 and influenza virus envelope glycoproteins results in a similarly rapid contraction of peripheral B-cell responses after boosting. J Infect Dis 2013; 207(3):426-31; PMID:23162135; http://dx.doi.org/10.1093/infdis/jis696
66. Sundling C, Forsell MN, O'Dell S, Feng Y, Chakrabarti B, Rao SS, Lore K, Mascola JR, Wyatt RT, Douagi I, et al. Soluble HIV-1 Env trimers in adjuvant elicit potent and diverse functional B cell responses in primates. J Exp Med 2010; 207(9):2003-17; PMID:20679401; http://dx.doi.org/10.1084/jem.20100025
67. Li Y, O'Dell S, Wilson R, Wu X, Schmidt SD, Hogerkorp CM, Louder MK, Longo NS, Poulsen C, Guenaga J, et al. HIV-1 neutralizing antibodies display dual recognition of the primary and coreceptor binding sites and preferential binding to fully cleaved envelope glycoproteins. J Virol 2012; 86(20):11231-41; PMID:22875963; http://dx.doi.org/10.1128/JVI.01543-12
68. Mouquet H, Klein F, Scheid JF, Warncke M, Pietzsch J, Oliveira TY, Velinzon K, Seaman MS, Nussenzweig MC. Memory B cell antibodies to HIV-1 gp140 cloned from individuals infected with clade A and B viruses. PLoS One 2011; 6(9):e24078; PMID:21931643; http://dx.doi.org/10.1371/journal.pone.0024078
69. Scheid JF, Mouquet H, Feldhahn N, Walker BD, Pereyra F, Cutrell E, Seaman MS, Mascola JR, Wyatt RT, Wardemann H, et al. A method for identification of HIV gp140 binding memory B cells in human blood. J Immunol Methods 2009; 343(2):65-7; PMID:19100741; http://dx.doi.org/10.1016/j.jim.2008.11.012
70. Sundling C, Li Y, Huynh N, Poulsen C, Wilson R, O'Dell S, Feng Y, Mascola JR, Wyatt RT, Karlsson Hedestam GB. High-resolution definition of vaccine-elicited B cell responses against the HIV primary receptor binding site. Sci Transl Med 2012; 4(142):142ra96; PMID:22786681; http://dx.doi.org/10.1126/scitranslmed.3003752
71. Sundling C, Zhang Z, Phad GE, Sheng Z, Wang Y, Mascola JR, Li Y, Wyatt RT, Shapiro L, Karlsson Hedestam GB. Single-cell and deep sequencing of IgG-switched macaque B cells reveal a diverse Ig repertoire following immunization. J Immunol 2014; 192(8):3637-44; PMID:24623130; http://dx.doi.org/10.4049/jimmunol.1303334
72. Wu X, Yang ZY, Li Y, Hogerkorp CM, Schief WR, Seaman MS, Zhou T, Schmidt SD, Wu L, Xu L, et al. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 2010; 329(5993):856-61; PMID:20616233; http://dx.doi.org/10.1126/science.1187659
73. Harris JW, Carr FJ, L AK. Recombinant humanized anti-human immunodeficiency virus antibody. Patent CA 2170034 C 2005
74. Major JG, Liou RS, Sun LK, Yu LM, Starnes SM, Fung MS, Chang TW, Chang NT. Construction and characterization of chimeric and humanized forms of a broadly neutralizing monoclonal antibody to HIV-1. Hum Antibodies Hybridomas 1994; 5(1-2):9-17; PMID:7858187; http://dx.doi.org/10.3233/HAB-1994-51-202
75. Sattentau QJ. Envelope Glycoprotein Trimers as HIV-1 Vaccine Immunogens. Vaccines (Basel) 2013; 1(4):497-512; PMID:26344344; http://dx.doi.org/10.3390/vaccines1040497
76. Miranda LR, Duval M, Doherty H, Seaman MS, Posner MR, Cavacini LA. The neutralization properties of a HIV-specific antibody are markedly altered by glycosylation events outside the antigen-binding domain. J Immunol 2007; 178(11):7132-8; PMID:17513762; http://dx.doi.org/10.4049/jimmunol.178.11.7132
77. Choe H, Li W, Wright PL, Vasilieva N, Venturi M, Huang CC, Grundner C, Dorfman T, Zwick MB, Wang L, et al. Tyrosine sulfation of human antibodies contributes to recognition of the CCR5 binding region of HIV-1 gp120. Cell 2003; 114(2):161-70; PMID:12887918; http://dx.doi.org/10.1016/S0092-8674(03)00508-7
78. Zhou P, Goldstein S, Devadas K, Tewari D, Notkins AL. Cells transfected with a non-neutralizing antibody gene are resistant to HIV infection:targeting the endoplasmic reticulum and trans-Golgi network. J Immunol 1998; 160(3):1489-96; PMID:9570571
79. Takeda S, Dorfman NA, Robert-Guroff M, Notkins AL, Rando RF. Two-phase approach for the expression of high-affinity human anti-human immunodeficiency virus immunoglobulin Fab domains in Escherichia coli. Hybridoma 1995; 14(1):9-18; PMID:7768538; http://dx.doi.org/10.1089/hyb.1995.14.9
80. Pene J, Gauchat JF, Lecart S, Drouet E, Guglielmi P, Boulay V, Delwail A, Foster D, Lecron JC, Yssel H. Cutting edge:IL-21 is a switch factor for the production of IgG(1) and IgG(3) by human B cells. J Immunol 2004; 172(9):5154-7; PMID:15100251; http://dx.doi.org/10.4049/jimmunol.172.9.5154
81. Dey AK, David KB, Lu M, Moore JP. Biochemical and biophysical comparison of cleaved and uncleaved soluble, trimeric HIV-1 envelope glycoproteins. Virology 2009; 385(1):275-81; PMID:19135223; http://dx.doi.org/10.1016/j.virol.2008.12.009
82. Sanders RW, Derking R, Cupo A, Julien JP, Yasmeen A, de Val N, Kim HJ, Blattner C, de la Pena AT, Korzun J, et al. A next-generation cleaved, soluble HIV-1 Env trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies. PLoS Pathog 2013; 9(9):e1003618; PMID:24068931; http://dx.doi.org/10.1371/journal.ppat.1003618
83. Ibeagha-Awemu Eveline E, AE. I, Zhao X. The influence of different anticoagulants and sample preparation methods on measurement of mCD14 on bovine monocytes and polymorphonuclear neutrophil leukocytes. BioMed Central 2012; 5:93; PMID:22333045; http://dx.doi.org/10.1186/1756-0500-5-93
84. Lefevre EA, Carr BV, Prentice H, Charleston B. A quantitative assessment of primary and secondary immune responses in cattle using a B cell ELISPOT assay. Vet Res 2009; 40(1):3; PMID:18828984; http://dx.doi.org/10.1051/vetres:2008041
85. Tiller T, Meffre E, Yurasov S, Tsuiji M, Nussenzweig MC, Wardemann H. Efficient generation of monoclonal antibodies from single human B cells by single cell RT-PCR and expression vector cloning. J Immunol Methods 2008; 329(1–2):112-124; PMID:17996249; http://dx.doi.org/10.1016/j.jim.2007.09.017
86. Center RJ, Wheatley AK, Campbell SM, Gaeguta AJ, Peut V, Alcantara S, Siebentritt C, Kent SJ, Purcell DFJ. Induction of HIV-1 subtype B and AE-specific neutralizing antibodies in mice and macaques with DNA prime and recombinant gp140 protein boost regimens. Vaccine 2009; 27(47):6605-12; PMID:19712773; http://dx.doi.org/10.1016/j.vaccine.2009.08.016
87. Montefiori DC. Measuring HIV neutralization in a luciferase reporter gene assay. Methods Mol Biol 2009; 485:395-405; PMID:19020839; http://dx.doi.org/10.1007/978-1-59745-170-3_26
88. The PyMOL Molecular Graphics System, Version 1.74 Schrödinger, LLC:New York, NY, USA, 2014. 2014.